Prevalence of HIV in Patients with Malignancy and of Malignancy in HIV Patients in a Tertiary Care Center from North India

Author(s): Sanjeev Sinha*, Ashish Agarwal, Kartik Gupta, Dibyakanti Mandal, Mitul Jain, Roger Detels, Karabi Nandy, Michelle A. DeVos, S.K. Sharma, N. Manoharan, P.K. Julka, G.K. Rath, Richard F. Ambinder, Ronald T. Mitsuyasu.

Journal Name: Current HIV Research

Volume 16 , Issue 4 , 2018

Submit Manuscript
Submit Proposal

Graphical Abstract:


Abstract:

Background and Objectives: People living with HIV/AIDS are at an increased risk of developing cancer. The goals of this study were to obtain data on the prevalence of HIV in the cancer population and vice versa at a major tertiary cancer and HIV center in North India.

Methods: This cross-sectional study was conducted over a 3-year period from July 2013 to June 2016, wherein successive HIV positive patients from an anti-retroviral therapy (ART) center were screened for malignancy. Simultaneously, successive cancer patients at the cancer center were screened for HIV. Baseline demographic details, risk factors, and laboratory investigations were obtained for all the patients.

Results: Among the 999 HIV-positive patients at the ART center, the prevalence of malignancy was 2% (n=20; 95% confidence interval (CI) 1.13, 2.87). Among the 998 patients with a malignancy, the prevalence of HIV infection was 0.9% (n=9; 95% CI 0.31, 1.49). Weight loss, loss of appetite, and fever were the most common symptoms in patients with HIV and cancer. Among 29 patients with HIV and cancer, AIDS-defining cancer was found in 19 patients; non-Hodgkin’s lymphoma was the most common malignancy reported (n=13).

Interpretation and Conclusion: There is a low prevalence of HIV in cancer patients as well as a low prevalence of cancer in HIV patients. AIDS-defining cancers remain much more common than non-AIDS-defining cancers. With the increased coverage of ART, it is expected that non-AIDSdefining cancers will increase, as is evident from data from more developed countries.

Keywords: AIDS-defining cancer, cancer, HIV, invasive cervical cancer, non-Hodgkin's lymphoma, ART.

[1]
Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS Lond Engl 2014; 28(4): 453-65.
[2]
Yarchoan R, Uldrick TS. HIV-Associated cancers and related diseases. N Engl J Med 2018; 378(11): 1029-41.
[3]
Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. JNCI J Natl Cancer Inst 2011; 103(9): 753-62.
[4]
Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20(12): 1645-54.
[5]
Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22(4): 489-96.
[6]
Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among hiv-infected persons and the impact of antiretroviral therapy: A 20-year cohort study. AIDS 2009; 23(1): 41-50.
[7]
Gill J, May M, Lewden C, Saag M. at al. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis Off Publ Infect Dis Soc Am 2010; 50(10): 1387-96.
[8]
Morlat P, Roussillon C, Henard S, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS Lond Engl 2014; 28(8): 1181-91.
[9]
Vandenhende M-A, Roussillon C, Henard S, et al. Cancer-related causes of death among hiv-infected patients in France in 2010: evolution since 2000. PLoS One 2015; 10(6): e0129550.
[10]
Centers for Disease Control (CDC). Update on acquired immune deficiency syndrome (AIDS)--United States. MMWR Morb Mortal Wkly Rep 1982; Sep 24 31(37): 507-508, 513-514.
[11]
Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF, Engels EA. Epidemiology of non-keratinocytic skin cancers among persons with acquired immunodeficiency syndrome in the US AIDS Lond Engl 2009 23(3): 385-93.
[12]
Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15(5): 629-33.
[13]
Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis Off Publ Infect Dis Soc Am 2012; 55(9): 1228-35.
[14]
Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol Off J Am Soc Clin Oncol 2009; 27(6): 884-90.
[15]
Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 1994; 266(5192): 1865-9.
[16]
Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92(18): 1500-10.
[17]
MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338(8773): 969-73.
[18]
Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993; 82(2): 619-24.
[19]
HIV/AIDS. World Health Organization. [cited 2018 Apr 30]. Available from: http://www.who.int/news-room/fact-sheets/detail/hiv-aids
[20]
UNAIDS, India. [cited 2018 Apr 30]. Available from:. http://www.unaids.org/en/regionscountries/countries/india
[21]
Paul TR, Uppin MS, Uppin SG, et al. Spectrum of malignancies in human immunodeficiency virus – positive patients at a tertiary care centre in South India. Indian J Cancer 2014; 51(4): 459.
[22]
Dhir AA, Sawant S, Dikshit RP, et al. Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control 2008; 19(2): 147-53.
[23]
Sachdeva RK, Sharma A, Singh S, Varma S. Spectrum of AIDS defining & non-AIDS defining malignancies in north India. Indian J Med Res 2016; 143(Suppl. 1): S129-35.
[24]
Agarwal B, Ramanathan U, Lokeshwas N, et al. Lymphoid neoplasms in HIV-positive individuals in India. J Acquir Immune Defic Syndr 2002; 29(2): 181-3.
[25]
OM - Revised Guidelines for ART | National AIDS Control Organization | MoHFW | GoI [Internet]. [cited 2018 Apr 30]. Available from: http://naco.gov.in/om-revised-guidelines-art
[26]
Crum-Cianflone N, Hullsiek KH, Marconi V, et al. Trends in the incidence of cancers among hiv-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS Lond Engl 2009; 23(1): 41-50.
[27]
Grulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM. Decreasing rates of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in the era of potent combination anti-retroviral therapy. AIDS Lond Engl 2001; 15(5): 629-33.
[28]
HIV Facts & Figures | National AIDS Control Organization | MoHFW | GoI. [cited 2018 May 4]. Available from: http://naco.gov.in/hiv-facts-figures
[29]
Phatak UA, Joshi R, Badakh DK, Gosavi VS, Phatak JU, Jagdale RV. AIDS-associated cancers: an emerging challenge. J Assoc Physicians India 2010; 58: 159-62.
[30]
Sharma S, Soneja M, Ranjan S. Malignancies in human immunodeficiency virus infected patients in India: Initial experience in the HAART era. Indian J Med Res 2015; 142(5): 563.
[31]
Venkatesh KK, Saghayam S, Devaleenal B, et al. Spectrum of malignancies among HIV-infected patients in South India. Indian J Cancer 2012; 49(1): 176.
[32]
Prem S, Narayanan G, Puthuveettil J. K J, K V. Spectrum of HIV/AIDS-associated cancers in south India. J Clin Oncol 2014; 32(15_suppl): e12534-e12534.
[33]
Sharma A, Bajpai J, Raina V, Mohanti BK. HIV-associated non-Hodgkin’s lymphoma: experience from a regional cancer center. Indian J Cancer 2010; 47(1): 35-9.
[34]
Ablashi D, Chatlynne L, Cooper H, Thomas D, Yadav M, Norhanom AW, et al. Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer 1999; 81(5): 893-7.
[35]
Munawwar A, Sharma SK, Gupta S, Singh S. Seroprevalence and determinants of kaposi sarcoma-associated human herpesvirus 8 in indian hiv-infected males. AIDS Res Hum Retroviruses 2014; 30(12): 1192-6.
[36]
MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet Lond Engl 1991; 338(8773): 969-73.
[37]
Uldrick TS, Little RF. How i treat classical hodgkin lymphoma in patients infected with human immunodeficiency virus Blood 2015; 125(8): 1226-35; 1355.
[38]
Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993; 82(2): 619-24.
[39]
Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, et al. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol 2015; 26(5): 958-66.
[40]
Cingolani A, Lepri AC, Teofili L, et al. Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One 2017; 12(10): e0186549.
[41]
Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for hiv-associated lymphoma in the antiretroviral therapy era. JNCI J Natl Cancer Inst 2013; 105(16): 1221-9.
[42]
Coutinho R, Pria AD, Gandhi S, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS 2014; 28(5): 689-97.
[43]
Hleyhel M, Belot A, Bouvier A-M, et al. Trends in survival after cancer diagnosis among HIV-infected individuals between 1992 and 2009. Results from the FHDH-ANRS CO4 cohort. Int J Cancer 2015; 137(10): 2443-53.
[44]
Besson C, Lancar R, Prevot S, et al. Outcomes for Hiv-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. AIDS 2017; 31(18): 2493-501.
[45]
Williams AB, Darragh TM, Vranizan K, Ochia C, Moss AR, Palefsky JM. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83(2): 205-11.
[46]
Chakravarty J, Chourasia A, Thakur M, Singh A, Sundar S, Agrawal N. Prevalence of human papillomavirus infection & cervical abnormalities in HIV-positive women in eastern India. Indian J Med Res 2016; 143(1): 79.
[47]
Goncalves PH, Montezuma-Rusca JM, Yarchoan R, Uldrick TS. Cancer prevention in HIV-infected populations. Semin Oncol 2016; Feb 43(1): 173-88.
[48]
Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116(5): 1167-73.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 4
Year: 2018
Page: [315 - 320]
Pages: 6
DOI: 10.2174/1570162X16666181018161616

Article Metrics

PDF: 20
HTML: 4